CJD WATCH MESSAGE BOARD
Lease this WebApp and get rid of the ads.
Immunotherapy in prion disease
Mon Dec 24, 2012 12:22
108.32.184.121

Review Nature Reviews Neurology, advance online publication, Published online 18 December 2012 | doi:10.1038/nrneurol.2012.258

Subject Categories: Spongiform encephalopathies | Neurodegenerative disease

Immunotherapy in prion disease

Yvonne Roettger, Yansheng Du, Michael Bacher, Inga Zerr, Richard Dodel & Jan-Philipp Bach About the authors

Top of page Abstract Transmissible spongiform encephalopathies (TSEs), also known as prion diseases, describe a group of fatal neurodegenerative disorders affecting both humans and animals. Accumulation of misfolded prion proteins is the pathological hallmark of these disorders; such accumulation occurs in lymphoreticular tissue prior to CNS involvement in scrapie, experimental models and human variant Creutzfeldt–Jakob disease. Lymphoreticular accumulation of misfolded prion protein has not been demonstrated in human sporadic or genetic forms of TSE. Once clinical symptoms develop, all prion disorders have a rapidly progressive and lethal course, and no effective therapy exists. In the past 10 years, antibody-based immunotherapy has been considered for other neurodegenerative disorders associated with protein misfolding and, therefore, might also be an effective approach to prevention or treatment of prion disease. Self-tolerance to endogenous prion protein is, however, a major challenge to the development of effective immunotherapy, as is the risk of adverse effects from active immunization. This Review summarizes the evidence that immunization could slow disease progression or increase lifespan in animal models of prion diseases. The therapeutic potential of these strategies in treating patients with prion diseases is also discussed.

Top of page Author affiliations Y. Roettger, Y. Du, M. Bacher, I. Zerr, R. Dodel & J. -P. Bach Department of Neurology, Philipps-University Marburg, Baldingerstrasse, 35043 Marburg, Germany (Y. Roettger, R. Dodel, J. -P. Bach). Department of Neurology, Indiana University School of Medicine, 975 West Walnut Street IB 457, Indianapolis, IN 46202, USA (Y. Du). Institute of Immunology, University of Marburg, Hans-Meerwein-Strasse, 35043 Marburg, Germany (M. Bacher). National Reference Centre for Transmissible Spongiform Encephalopathies, Department of Neurology, Georg-August-University Göttingen, Robert-Koch-Strasse 40, 37075 Göttingen, Germany (I. Zerr).

Correspondence to: R. Dodel dodel@med.uni-marburg.de

Published online 18 December 2012


http://www.nature.com/nrneurol/journal/vaop/ncurrent/abs/nrneurol.2012.258.html




December 13, 2012

The rise and fall of pentosan polysulfate in prion disease

http://prionpps.blogspot.com/2012/12/the-rise-and-fall-of-pentosan.html




TSS




Monday, December 24, 2012

Immunotherapy in prion disease

http://prionpps.blogspot.com/2012/12/immunotherapy-in-prion-disease.html





Click here to receive daily updates
RETURN TO CJD WATCH